Varenicline as a Treatment for Methamphetamine Dependence

Baylor College of Medicine

Status and phase

Completed

Phase 1

Conditions

Methamphetamine Dependence

Substance Abuse

Methamphetamine Abuse

Treatments

Drug: Placebo

Drug: Varenicline

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT01571167

1R01DA027134-01 (U.S. NIH Grant/Contract)

H-26875

DPMC

Details and patient eligibility

About

The primary purpose of the study is to determine the effects of treatment with varenicline (1 and 2 mg daily), compared to treatment with placebo, on methamphetamine-induced craving and subjective effects in methamphetamine-dependent human volunteers.

Full description

This study is part of an effort to develop treatments for methamphetamine abuse. Varenicline is a drug that changes levels of certain brain chemicals that may also be useful in helping people to stop using methamphetamine. Our goal is to determine the safety and effects of varenicline (1 and 2 mg, daily, vs. a placebo) when it is used before experimental administration of methamphetamine, on a number of physical and psychological measures; specifically blood pressure, heart rate, and how you feel after taking methamphetamine. The secondary purpose is to determine the effects of treatment with varenicline (1 and 2 mg daily), compared to treatment with placebo, on the reinforcing effects of methamphetamine by measuring methamphetamine self-administration in methamphetamine-dependent human volunteers.

Enrollment

17 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

In order to participate in the study, participants must:

Be English-speaking volunteers who are not seeking treatment at the time of the study
Be between 18-55 years of age
Meet DSM-IV TR criteria for MA dependence
Must be cigarette smokers, defined as smoking 10 or more cigarettes per day by self-report
Have a self-reported history of using MA by the smoked or IV route and provide at least one MA-positive urine prior to admission
Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 105-150 mm Hg systolic and 45-90 mm Hg diastolic; this criterion must be met within 2 days of admission
Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) < 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) < 2 x the upper limit of normal
Have a baseline EKG that demonstrates normal sinus rhythm, normal conduction (including QTc), and no clinically significant arrhythmias
Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician or nurse practitioner and the principal investigator.

Exclusion criteria

Subjects will be excluded if they:

Have any previous medically adverse reaction to METH, including loss of consciousness, chest pain, or epileptic seizure
Have neurological or psychiatric disorders, as assessed by MINI, such as: episode of major depression within the past 2 years; lifetime history of schizophrenia, other psychotic illness, or bipolar illness; current organic brain disease or dementia assessed by clinical interview; history of or any current psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months and/or current suicidal ideation/plan; history of psychosis occurring in the absence of current METH use
Meet DSM-IV criteria for abuse/dependence on alcohol or other drugs, except nicotine or marijuana
Have used methamphetamine only by the intravenous route
Have evidence of clinically significant heart disease or hypertension, as determined by physician
Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease
Have HIV and currently symptomatic, have a diagnosis of AIDS, or currently taking antiretroviral medication
Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, and throughout the study
Have any history of asthma, chronic coughing and wheezing, or other chronic respiratory illnesses
Currently use alpha or beta agonists, theophylline, or other sympathomimetics
Have made a suicide attempt in the past year
Have any other illness, condition, or use of medications, which in the opinion of the PI and/or the admitting physician would preclude safe and/or successful completion of study.

Criteria for Discontinuation Following Initiation:

Positive urine drug screen or breath test indicating illicit use of cocaine, MA, alcohol, opiates, or other abused drugs not delivered as part of this protocol
Inability to comply with study procedures
Meet discontinuation criteria due to exaggerated response to MA, described below
Nausea severe enough to require treatment.

Rationale for Subject Selection Criteria:

Participants are required to have used MA by the smoked or IV route to avoid exposing participants to routes of administration that produce more intensive interoceptive effects. The age criteria were selected primarily to avoid enrolling participants with undiagnosed cardiovascular disease. Participants with active HIV disease are excluded to avoid potential exacerbation of their underlying disease; participants with asymptomatic HIV are included because this group is at high risk for MA dependence. Participants with asthma (or who take asthma medications) are excluded due to potential adverse interactions between beta agonist medications and MA.